Home › Funds › Avoro Capital Advisors LLC › ASND

Avoro Capital Advisors LLC position in ASND

ASCENDIS PHARMA A/S · Health Care

Avoro Capital Advisors LLC reported holding 5,050,000 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$1.15B, representing 11.90% of its reported portfolio and ranking #2 among its reported holdings. Avoro Capital Advisors LLC has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)5.05M sh
Reported value held$1.15B
Portfolio Weight11.90%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Avoro Capital Advisors LLC's ASND position evolved

Avoro Capital Advisors LLC first disclosed a stake in ASND in Q3 2023 at 3,670,000 shares (US$343.7M). The position peaked in Q2 2026 at 5,111,111 shares, worth US$1.36B. Across 13 filings, Avoro Capital Advisors LLC increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 5,050,000 shares valued at US$1.15B — a reduction of -61,111 shares quarter over quarter.. Notable position changes include a 99% trim in Q4 2025 (shares rose 7% over the following quarter), a 10025% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.67M $343.66M New
Q4 2023 3.76M $473.01M Add
Q1 2024 3.97M $599.64M Add
Q2 2024 4.20M $572.34M Add
Q3 2024 4.99M $744.89M Add
Q4 2024 5.10M $702.54M Add
Q1 2025 5.22M $813.28M Add
Q2 2025 4.98M $859.55M Reduce
Q3 2025 5.11M $1.02B Add
Q4 2025 50.00K $625.00K Reduce
Q1 2026 5.06M $1.16B Add
Q2 2026 5.11M $1.36B Add
Q3 2026 5.05M $1.15B Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 35 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), WESTFIELD CAPITAL MANAGEMENT CO LP (US$1.17B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has Avoro Capital Advisors LLC held ASND?

Avoro Capital Advisors LLC has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Avoro Capital Advisors LLC's current position in ASND?

As of Q3 2026, Avoro Capital Advisors LLC holds 5.05M shares of ASND (ASCENDIS PHARMA A/S), valued at $1.15B, representing 11.90% of its reported portfolio and ranking #2.

Has Avoro Capital Advisors LLC been buying or selling ASND?

In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in ASND. The position peaked in Q2 2026 at 5.11M shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., WESTFIELD CAPITAL MANAGEMENT CO LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.